Safusidenib for people with IDH-mutant glioma whose tumor progressed on vorasidenib
Part of Cancer clinical trials.
This trial tests a new targeted therapy called safusidenib for people whose brain tumor (glioma) has an IDH1 mutation and who have already taken vorasidenib but the tumor kept growing. The study aims to see if safusidenib can help when vorasidenib stops working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a grade 2 or 3 glioma (brain tumor) that is IDH-mutant (a specific genetic change).
- You have had at least one surgery for the tumor (biopsy or removal).
- Your tumor can be seen and measured on an MRI scan.
- You were previously treated with vorasidenib, and your tumor grew during that treatment.
- You have not received any other treatments for the glioma besides surgery and vorasidenib.
- You are expected to live at least 12 more months, and your blood counts and organ function are adequate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the targeted drug vorasidenib to standard chemotherapy (temozolomide) after radiation helps people with a specific type of advanced brain cancer called IDH-mutant astrocytoma. It is for patients who have not had previous treatments like chemotherapy or radiation and whose tumors have certain genetic features.
This Phase 3 trial tests safusidenib, a targeted medicine, to help stop or slow the return of certain brain tumors with an IDH1 mutation. It focuses on people after initial treatment (surgery and/or radiation and temozolomide), aiming to improve outcomes during maintenance therapy.
This trial tests an experimental pill called safusidenib for people with a slow-growing brain tumor (grade 2 glioma) that has an IDH1 mutation. The goal is to see if it can control the tumor and improve outcomes.
This trial tests the drug vorasidenib for people with a slow-growing brain tumor (Grade 2 glioma) that has an IDH mutation. The goal is to see how well the drug works and how it affects your quality of life.
This trial tests whether the drug vorasidenib, guided by a special PET scan, can help people with certain low-grade brain tumors that have come back or are still present after surgery. It aims to see if this approach is safe and effective.
This trial tests a combination of two oral medications, olutasidenib and temozolomide, for people with a specific type of aggressive brain tumor (high-grade glioma) that has an IDH1 mutation. The goal is to see if this combination can help control the tumor after standard treatment like radiation.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.